Store
GS2 · Health

Backgrounder: GLP-1 drugs: use, risks and regulation

1 min readHealth
Battle IAS current affairs title card: Backgrounder: GLP-1 drugs: use, risks and regulation (GS2 · Health, 1 April 2026)

What happened

  • PIB explained GLP-1 drugs for diabetes and obesity, their risks and regulation [PIB].

Background

  • GLP-1 agonists (semaglutide etc.) need prescription; CDSCO regulates approvals.

Why it matters

  • These drugs help with diabetes and obesity but are also misused, so regulation matters.

How to use this in Mains

GS-II Issues relating to development and management of health

  1. As per PIB (2026-04-01): PIB explained GLP-1 drugs for diabetes and obesity, their risks and regulation.
  2. These drugs help with diabetes and obesity but are also misused, so regulation matters.
Quotable data point

PIB explained GLP-1 drugs for diabetes and obesity, their risks and regulation.

PIB: PIB Backgrounder: GLP-1 drugs, 1 Apr 2026

Exam angle

UPSC

Prelims: GLP-1.

Practice MCQs

Original practice questions (not PYQs).

Practice · UPSC

GLP-1 drugs treat

Answer (a) & explanation

PIB.

Practice · UPSC

Regulator

Answer (a) & explanation

PIB.

Practice · UPSC

Example

Answer (a) & explanation

PIB.

Go deeper

ExplainerOne Health Approach: Why Human, Animal and Environmental Health Are Linked, Zoonotic Diseases, the Global Quadripartite and India’s National One Health Mission (UPSC Notes + PYQs)ExplainerAntimicrobial Resistance (AMR): How Superbugs Arise, the Global and Indian Burden, Causes in Hospitals, Farms and the Environment, and India’s National Action Plan 2.0 (UPSC Notes + PYQs)

Official source: PIB: PIB Backgrounder: GLP-1 drugs, 1 Apr 2026

facts from cited sources only; faculty review pending